Gene · 4017
Papers2,536
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,536
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| LOXL2 serves as a prognostic biomarker associated with immune landscape in lung adenocarcinoma. | Asian J Surg | 2024 | 39550267 | PubTator, text mining | PubMed |
| ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer. | NPJ Precis Oncol | 2024 | 39496753 | PubTator, text mining | PubMed |
| siLOXL2 Inhibits Endothelial Inflammatory Response and EndMT Induced by ox-LDL. | Cerebrovasc Dis Extra | 2024 | 39419008 | PubTator, text mining | PubMed |
| A comprehensive lifestyle index and its associations with DNA methylation and type 2 diabetes among Ghanaian adults: the rodam study. | Clin Epigenetics | 2024 | 39415250 | PubTator, text mining | PubMed |
| Pulling the Rug Out from Under: Biomechanical Microenvironment Remodeling for Induction of Hepatic Stellate Cell Quiescence. | Adv Mater | 2024 | 39410721 | PubTator, text mining | PubMed |
| Preventive Effect of 3,3'-dimethoxy-4,4'-dihydroxy-stilbene Triazole on Pulmonary Fibrosis through Inhibition of Inflammation and Down-regulation of TGF-b Signaling Pathway. | Dokl Biochem Biophys | 2024 | 39400768 | PubTator, text mining | PubMed |
| Correlation of LOXL2 expression in non-small cell lung cancer with immunotherapy. | Int J Clin Exp Pathol | 2024 | 39399656 | PubTator, text mining | PubMed |
| Analysis and functional validations of multiple cell death patterns for prognosis in prostate cancer. | Int Immunopharmacol | 2024 | 39353397 | PubTator, text mining | PubMed |
| Serum LOXL2 is Elevated and an Independent Biomarker in Patients with Coronary Artery Disease. | Int J Gen Med | 2024 | 39295855 | PubTator, text mining | PubMed |
| Retraction: LOXL2 upregulation in gliomas drives tumorigenicity by activating autophagy to promote TMZ resistance and trigger EMT. | Front Oncol | 2024 | 39257553 | PubTator, text mining | PubMed |
| Hypoxia and Foxn1 alter the proteomic signature of dermal fibroblasts to redirect scarless wound healing to scar-forming skin wound healing in Foxn1-/- mice. | BMC Biol | 2024 | 39256768 | PubTator, text mining | PubMed |
| Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. | Gut | 2024 | 39251327 | PubTator, text mining | PubMed |
| Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier. | Neuron | 2024 | 39191260 | PubTator, text mining | PubMed |
| Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. | Cell Rep Med | 2024 | 39173635 | PubTator, text mining | PubMed |
| The extracellular matrix component perlecan/HSPG2 regulates radioresistance in prostate cancer cells. | Front Cell Dev Biol | 2024 | 39149513 | PubTator, text mining | PubMed |
| LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis. | J Clin Invest | 2024 | 39145451 | PubTator, text mining | PubMed |
| A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. | Cell Chem Biol | 2024 | 39043186 | PubTator, text mining | PubMed |
| Sex differences and role of lysyl oxidase-like 2 in angiotensin II-induced hypertension in mice. | Am J Physiol Heart Circ Physiol | 2024 | 39028284 | PubTator, text mining | PubMed |
| MiR-4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression. | J Zhejiang Univ Sci B | 2024 | 39011679 | PubTator, text mining | PubMed |
| LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension. | Am J Physiol Lung Cell Mol Physiol | 2024 | 39010824 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4017/papers?page=8